#London #United Kingdom #Roche Diagnostics #Kinomica #Michele Pedrocchi

Michele Pedrocchi Takes Helm as Chair of Kinomica's Board of Directors

Kinomica Ltd., a frontrunner in the development of precision oncology diagnostics, has made a significant leadership change with the appointment of Dr. Michele Pedrocchi as its new Chair of the Board of Directors. This strategic move is expected to bolster the company's efforts in delivering innovative diagnostic solutions that can effectively guide cancer treatment.

Dr. Pedrocchi comes with an impressive background of over 30 years in the life sciences and in-vitro diagnostics sectors. His previous role as Roche Diagnostics' Global Head of Strategy and Business Development equipped him with extensive knowledge and insights about the market and the intricate factors that contribute to a company's growth. As a former member of Roche's Executive Committee, he played a pivotal role in shaping the direction of the company, particularly in commercial strategies and product innovation.

His contributions to the field are noteworthy; Dr. Pedrocchi was instrumental in establishing Polymerase Chain Reaction (PCR) as a standard diagnostic methodology across Europe. Moreover, he pioneered the integration of Companion Diagnostics (CDx) to facilitate targeted oncology treatments, significantly impacting patient outcomes. Dr. Pedrocchi has also ventured into digital health solutions, further solidifying his reputation as a leader at the intersection of innovation and health.

Tim Fell, the Chief Executive Officer of Kinomica, expressed enthusiasm about Dr. Pedrocchi's appointment, emphasizing his ability to translate groundbreaking diagnostic innovations into routine clinical practices. “Michele's leadership and expertise will be invaluable as Kinomica seeks to integrate phosphoproteomic diagnostics for therapeutic selection. His vast experience aligns perfectly with our mission to enhance cancer care,” he remarked.

Expressing his excitement, Dr. Pedrocchi stated, “I am thrilled to be taking on this role as Kinomica has tremendous potential to contribute fundamentally to precision medicine. This world-class team of scientists has made impressive progress in harnessing the power of phosphoproteomics to guide cancer treatment choices. Our primary goal is to make these proprietary insights accessible to as many patients as possible.”

The timing of this leadership transition coincides with a successful financing round led by Mercia Ventures, along with contributions from other renowned investors including BGF* and Longwall Ventures. This influx of capital reflects confidence in Kinomica’s vision and its ongoing efforts to enhance its Board of Directors. The appointments of Dr. Robert Hornby and Joanna Smart as directors for Mercia Ventures and BGF respectively further strengthen the team, bringing a wealth of knowledge and experience to the company.

About Kinomica

Kinomica is at the forefront of precision oncology diagnostics, harnessing a robust platform known as KScan®. This advanced phosphoproteomic diagnostic system aids clinicians in understanding which approved therapeutics are most likely to benefit individual patients, thereby optimizing treatment strategies and enhancing clinical decision-making. For more information about Kinomica and its innovative solutions, visit www.kinomica.com and follow the company on LinkedIn for the latest updates and insights.

As the landscape of healthcare continues to evolve, Kinomica, under Dr. Pedrocchi's leadership, is well-positioned to redefine the future of cancer diagnostics and patient care.